Jove
Visualize
联系我们
JoVE
x logofacebook logolinkedin logoyoutube logo
关于 JoVE
概览领导团队博客JoVE 帮助中心
作者
出版流程编辑委员会范围与政策同行评审常见问题投稿
图书馆员
用户评价订阅访问资源图书馆顾问委员会常见问题
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experiments存档
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教师资源中心教师网站
使用条款与条件
隐私政策
政策

相关概念视频

Peptic Ulcer Disease I: Introduction01:30

Peptic Ulcer Disease I: Introduction

162
Peptic Ulcer Disease (PUD) is characterized by mucosal excavation in the esophagus, stomach, pylorus, or duodenum. It can manifest as acute or chronic based on the extent and duration of mucosal involvement.
An acute ulcer, marked by superficial erosion and minimal inflammation, swiftly resolves upon identifying and addressing the underlying cause. In contrast, a chronic ulcer persists, potentially eroding through the muscular wall and forming fibrous tissue.
Peptic ulcers can also be...
162
Pathophysiology of Peptic Ulcer Disease: Mucosal Defense Factors01:24

Pathophysiology of Peptic Ulcer Disease: Mucosal Defense Factors

375
Peptic ulcer disease, commonly called PUD, represents a multifaceted condition characterized by disruptions in the lining of the gastrointestinal (GI)  tract. Central to the protection of the gastrointestinal lining is the mucosal-bicarbonate barrier. This physiological defense mechanism is a formidable shield against the corrosive effects of gastric acid and pepsin secretion in the stomach. Its role is pivotal in maintaining the structural integrity of the stomach's inner lining.
375
Peptic Ulcer Disease IV: Management01:26

Peptic Ulcer Disease IV: Management

87
Medical treatment strategies for peptic ulcers encompass various methods. The primary goal of treatment is to diminish gastric acidity and strengthen mucosal defense mechanisms.
The therapeutic approach involves ensuring adequate rest, implementing drug therapy, promoting smoking cessation, making dietary modifications, and emphasizing long-term follow-up care.
Pharmacological management
The prevailing therapy for peptic ulcers involves a combination of managing the patient's current...
87
Peptic Ulcer Disease II: Pathophysiology01:28

Peptic Ulcer Disease II: Pathophysiology

374
Peptic Ulcer Disease (PUD) is characterized by the development of ulcers in the stomach or duodenal mucosa. Its pathophysiology is complex, involving a balance between damaging and protective elements.
Damaging agents such as Helicobacter pylori, gastric acid, pepsin, and nonsteroidal anti-inflammatory drugs (NSAIDs) can weaken the mucosal defense, allowing hydrogen ions to infiltrate back and harm epithelial cells.
374
Peptic Ulcer Disease III: Clinical Manifestations and Diagnostic Studies01:28

Peptic Ulcer Disease III: Clinical Manifestations and Diagnostic Studies

109
Peptic ulcer disease (PUD) presents with diverse symptoms depending on the location and severity of the ulcer. Clinical manifestations of peptic ulcer include dull pain and a burning sensation in the mid-epigastric region.
Few clinical manifestations differentiate gastric ulcers from duodenal ulcers. Distinctions in the location, timing, and pain relief are crucial for healthcare providers in differentiating between gastric and duodenal ulcers during clinical assessments.
109
Acid Suppressive Drugs for Peptic Ulcer Disease: Proton Pump Inhibitors01:13

Acid Suppressive Drugs for Peptic Ulcer Disease: Proton Pump Inhibitors

374
Peptic ulcers, often induced by H. pylori infections or NSAID usage, arise from disruptions in the delicate balance of gastric acid production. Peptic ulcers stem from heightened gastric acid levels due to H. pylori infections or NSAID use. The protective mucus layer diminishes in the presence of these factors, allowing gastric acid to erode the stomach lining and form ulcers.
Gastric acid, a potent cocktail of hydrogen and chloride ions, is produced in specialized parietal cells within the...
374

您也可能阅读

相关文章

通过共同作者、期刊和引用图与本文相关的文章。

排序
Same author

Measuring patriotic emotional granularity: task-based validation, brief scale development, and cross-method evidence.

BMC psychology·2026
Same author

Should we screen for colorectal cancer with biennial FIT beginning at age 45 in Canada?

Journal of the Canadian Association of Gastroenterology·2026
Same author

MGDP: Mastering a Generalized Depth Perception Model for Quadruped Locomotion.

Advanced science (Weinheim, Baden-Wurttemberg, Germany)·2026
Same author

Saudi consensus statements on the management of irritable bowel syndrome.

Saudi journal of gastroenterology : official journal of the Saudi Gastroenterology Association·2026
Same author

Future Global Outlook in Gastrointestinal and Liver Disorders: Consensus and Perspectives from the Leaders of Member Societies of the World Gastroenterology Organization.

Journal of gastrointestinal and liver diseases : JGLD·2026
Same author

Immunomodulatory effects of biodegradable Mg-Cu-Zn alloy in esophageal cancer.

Bioactive materials·2026

相关实验视频

Updated: Jun 23, 2025

The Dyspepsia Educational Tool As a Novel Aid in Dyspepsia Management
06:40

The Dyspepsia Educational Tool As a Novel Aid in Dyspepsia Management

Published on: June 29, 2019

6.6K

胃潰瘍疾病

Majid A Almadi1, Yidan Lu2, Ali A Alali3

  • 1Division of Gastroenterology, King Khalid University Hospital, King Saud University, Riyadh, Saudi Arabia; Division of Gastroenterology, The McGill University Health Center, Montréal General Hospital, McGill University, Montréal, QC, Canada.

Lancet (London, England)
|June 17, 2024
PubMed
概括

胃潰瘍疾病通常是由H. pylori或藥物引起的,使用酸性抑制和H. pylori根除來控制. 适当的质子抑制剂 (PPI) 使用是关键,如果不再适用,则考虑取消处方.

更多相关视频

Author Spotlight: Advancing Early Detection and Treatment of Gastrointestinal Tumors
03:05

Author Spotlight: Advancing Early Detection and Treatment of Gastrointestinal Tumors

Published on: February 16, 2024

1.0K
Gastric Mucosa Quantitative Polymerase Chain Reaction Analysis for Detecting Helicobacter pylori and Antibiotic Resistance
05:23

Gastric Mucosa Quantitative Polymerase Chain Reaction Analysis for Detecting Helicobacter pylori and Antibiotic Resistance

Published on: March 7, 2025

305

相关实验视频

Last Updated: Jun 23, 2025

The Dyspepsia Educational Tool As a Novel Aid in Dyspepsia Management
06:40

The Dyspepsia Educational Tool As a Novel Aid in Dyspepsia Management

Published on: June 29, 2019

6.6K
Author Spotlight: Advancing Early Detection and Treatment of Gastrointestinal Tumors
03:05

Author Spotlight: Advancing Early Detection and Treatment of Gastrointestinal Tumors

Published on: February 16, 2024

1.0K
Gastric Mucosa Quantitative Polymerase Chain Reaction Analysis for Detecting Helicobacter pylori and Antibiotic Resistance
05:23

Gastric Mucosa Quantitative Polymerase Chain Reaction Analysis for Detecting Helicobacter pylori and Antibiotic Resistance

Published on: March 7, 2025

305

科学领域:

  • 胃肠病学
  • 内部医学
  • 药理学

背景情况:

  • 胃潰瘍疾病 (PUD) 每年影響0.12%至1.5%.
  • 常见的原因包括Helicobacter pylori感染,NSAID/阿司匹林使用,严重疾病或异常因素.
  • 治疗包括消除H. pylori,抑制酸性 (通常是质子抑制剂) 和治疗出血等并发症.

研究的目的:

  • 审查目前对胃病的治疗策略.
  • 讨论治疗抗血小板/抗血栓剂的患者的特殊考虑.
  • 要突出不断发展的H. pylori治疗和预防指南.

主要方法:

  • 对PUD管理指南和研究的文献综述.
  • 对H. pylori感染和酸性抑制的治疗方法的分析.
  • 检查预防指示和新兴疗法.

主要成果:

  • 选择的治疗方法取决于局部抗生素耐药性.
  • 对于高风险患者来说,建议使用PPI进行预防.
  • 与相竞争的酸阻塞剂和H.pylori疫苗是未来研究的领域.

结论:

  • 对于已批准的适用药物来说,适当的PPI使用通常会超过风险.
  • 治疗时应考虑停止使用PPI.
  • 需要进一步研究压力出血的管理和最佳的患者/治疗选择.